Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
URL: http://harvard.eagle-i.net/i/0000012d-c90c-c8fc-4882-b08d80000000
Proper Citation: DF/HCC Cell Manipulation Core Facility (RRID:SCR_009734)
Description:
Core facility that provides the following services: Hematopoietic progenitor cell (HPC) components processing, Tumor cell vaccine generation, Dendritic cell vaccine generation, Validation consultation.
The (Connell and O''Reilly Families) Cell Manipulation Core Facility (CMCF), at Dana-Farber Cancer Institute (DFCI) was created in 1996 to be the manufacturing facility that produces safe and effective novel cellular component therapy that meets regulatory guidelines for clinical use and also facilitates research to be translated from the bench to the bedside. The goal of this facility is to assist DF/HCC investigators in developing new cell-based therapies for cancer and to support clinical research studies designed to evaluate the toxicity and efficacy of these novel treatments. In November 2004, CMCF moved to a newly constructed 6,700 square feet facility on the third floor and ground floor of the Jimmy Fund Building (JFB) at DFCI. The new facility is dedicated to the production of clinical grade cellular products for patients who participate in clinical trials conducted by DF/HCC investigators. All procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices (cGMP) for cell and tissue processing. The third floor accommodates all of the production areas while space on the ground floor is devoted to the long-term storage of cellular products, tissues and samples in liquid nitrogen and mechanical freezers. The CMCF is available to both clinical and laboratory investigators at all DF/HCC institutions and will provide services to patients at all DF/HCC affiliated hospitals. The staff of the CMCF are committed to working with DF/HCC investigators at all levels of clinical trial development and execution, including pre-clinical development, trial design, DF/HCC and FDA review, data management, quality control, internal and external audits as well as reports and publications. The Cell Manipulation Core Facility (CMCF) has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). The CMCF services as a Regulatory Core for Center for Human Cell Therapy and is also a member of the Joint Program in Transfusion Medicine.
Abbreviations: DF/HCC CMCF
Resource Type: service resource, access service resource, core facility
Keywords: ex vivo genetic manipulation of cells, vaccine preparation, validation
Expand Allis listed by |
|
has parent organization |
We found {{ ctrl2.mentions.total_count }} mentions in open access literature.
We have not found any literature mentions for this resource.
We are searching literature mentions for this resource.
Most recent articles:
{{ mention._source.dc.creators[0].familyName }} {{ mention._source.dc.creators[0].initials }}, et al. ({{ mention._source.dc.publicationYear }}) {{ mention._source.dc.title }} {{ mention._source.dc.publishers[0].name }}, {{ mention._source.dc.publishers[0].volume }}({{ mention._source.dc.publishers[0].issue }}), {{ mention._source.dc.publishers[0].pagination }}. (PMID:{{ mention._id.replace('PMID:', '') }})
Check
for all resource mentions.
A list of researchers who have used the resource and an author search tool
A list of researchers who have used the resource and an author search tool. This is available for resources that have literature mentions.
No rating or validation information has been found for DF/HCC Cell Manipulation Core Facility.
No alerts have been found for DF/HCC Cell Manipulation Core Facility.
Source: SciCrunch Registry
